drugset
drugset / Trial / NCT00654277

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

NCT00654277 ↗

Phase 1 Completed 32 enrolled Par Pharmaceutical, Inc. Algorithme Pharma Inc · collab
RandomizedCrossoverOpen-label

Summary

To compare the single-dose bioavailability of Ondansetron 8 mg oDT and Zofran 8 mg ODT

Timeline

Start
2002-08
Primary completion
2002-09
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 8 mg —

Indications

No indication recorded.